c-Kit (N822K)

KIT · Variant type: point · HGVS: p.N822K

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	98.5%	1.5%	93.43
2	Ripretinib	97.1%	2.9%	92.95
3	Tivozanib	96.9%	3.1%	92.42
4	Avapritinib	96.3%	3.7%	97.73
5	Pacritinib	96.2%	3.8%	88.64
6	Erdafitinib	96.0%	4.0%	95.71
7	Gilteritinib	94.9%	5.1%	88.97
8	Selpercatinib	94.6%	5.4%	96.72
9	Sunitinib	92.5%	7.5%	91.73
10	Apatinib	91.5%	8.5%	97.73
11	Sorafenib	90.6%	9.4%	96.72
12	Fedratinib	90.0%	10.0%	96.21
13	Vandetanib	88.1%	11.9%	95.74
14	Umbralisib	86.3%	13.7%	98.74
15	Mitapivat	80.7%	19.4%	100.00
16	Quizartinib	78.0%	22.0%	99.50
17	Capivasertib	75.5%	24.5%	96.48
18	Upadacitinib	73.0%	27.1%	97.98
19	Entrectinib	66.4%	33.6%	93.69
20	Pexidartinib	64.9%	35.1%	99.49
21	Alpelisib	64.5%	35.5%	97.22
22	Deucravacitinib	63.3%	36.7%	98.99
23	Pemigatinib	60.5%	39.5%	98.23
24	Repotrectinib	53.6%	46.4%	84.21
25	Tenalisib	53.0%	47.0%	97.98

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	98.5%	—	—
Ripretinib	97.1%	—	—
Tivozanib	96.9%	—	—
Avapritinib	96.3%	—	—
Pacritinib	96.2%	—	—
Erdafitinib	96.0%	—	—
Gilteritinib	94.9%	—	—
Selpercatinib	94.6%	—	—
Sunitinib	92.5%	—	—
Apatinib	91.5%	—	—
Sorafenib	90.6%	—	—
Fedratinib	90.0%	—	—
Vandetanib	88.1%	—	—
Umbralisib	86.3%	—	—
Mitapivat	80.7%	—	—
Quizartinib	78.0%	—	—
Capivasertib	75.5%	—	—
Upadacitinib	73.0%	—	—
Entrectinib	66.4%	—	—
Pexidartinib	64.9%	—	—
Alpelisib	64.5%	—	—
Deucravacitinib	63.3%	—	—
Pemigatinib	60.5%	—	—
Repotrectinib	53.6%	—	—
Tenalisib	53.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.1ms